Read more here
Welcome to OncoGeneX
News & Events
Tuesday, May 28 2013
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference
Thursday, May 23 2013
OncoGenex Announces Plans for the Initiation of the Cedar™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Squamous...
Wednesday, May 22 2013
OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting
Exploring New Compounds to Meet the Challenge of Cancer Treatment Resistance
OncoGenex is a leader in the development of novel therapeutics that target important mechanisms of treatment resistance in cancer. We are committed to the development and commercialization of first-in-class, innovative therapies that have the potential to redefine treatment outcomes for patients with a variety of cancers.
Learn more about cancer treatment resistance.
Product Pipeline
Phase 3
OncoGenex’ lead compound, custirsen, is an experimental drug designed to block the production of the protein clusterin, which may play a fundamental role in cancer cell survival and treatment resistance. Clusterin is upregulated in tumor cells in response to treatment interventions such as chemotherapy, hormone ablation and radiation therapy and has been found to be overexpressed in a number of cancers, including prostate, lung, breast and bladder. Increased clusterin production has been linked to faster rates of cancer progression, treatment resistance and shorter survival duration.
Information:
For PatientsFor PhysiciansFor InvestorsPhase 2
OGX-427 is a once-weekly intravenous (IV) experimental drug designed to inhibit the production of heat shock protein 27 (Hsp27), a protein that is elevated in many cancers and that has been shown to promote cancer cell growth and tumor metastasis. By inhibiting Hsp27, OGX-427 may disable cancer cells’ defenses and overcome treatment resistance. Both the potential single-agent activity and synergistic activity of OGX-427 with cancer treatments may increase the overall benefit of existing therapies and augment the durability of treatment outcomes, which could lead to increased patient survival.
